This enduring education is aimed at providing pulmonologists, respirologists, and allergists/immunologists with an update on the recommended use of biologics in the treatment of moderate-to-severe asthma. By the end of the sessions, learners will be better able to: 1: Review recommended management strategies for moderate-to-severe asthma; 2: Explain the rationale for the use of biologics in the treatment of patients with moderate-to-severe asthma; 3: Identify patients eligible for systemic therapy for the treatment of moderate-to-severe asthma; and, 4: Outline evidence-based, long-term strategies to improve lung function in patients with moderate-to-severe asthma. Downloadable slides and podcast are available for learners to use in their clinical setting.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/TSJ
- Start Date: 2024-12-23 06:00:00
- End Date: 2024-12-23 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Sanofi-Genzyme - Amount: 208454.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all